Gilead oncology chief departing to head up Glenmark spin-out

Gilead oncology chief departing to head up Glenmark spin-out

Source: 
Biopharma Dive
snippet: 

Gilead's head of oncology, Alessandro Riva, will step down at the end of the month to become CEO of a newly spun-out company from Indian drugmaker Glenmark Pharmaceuticals, leaving Gilead at a critical moment for the biotech's ambitions in cancer research.